Regulatory Information
PROCTER & GAMBLE (SINGAPORE ) PTE LTD
PROCTER & GAMBLE (SINGAPORE) PTE LTD
Therapeutic
General Sale List
Formulation Information
SOLUTION
**Dosage, mode of administration**  Iliadin 0.025% Decongestant Nasal Drops is indicated in children aged between 1 and 6 years. Iliadin 0.025% Decongestant Nasal Drops is intended for intranasal application. Unless otherwise prescribed, instill 1–2 drops of Iliadin 0.025% Decongestant Nasal Drops into each nostril 2–3 times daily. **Duration of treatment** Unless specifically prescribed by the doctor, Iliadin 0.025% Decongestant Nasal Drops should only be used for short periods of time (5 to 7 days). A treatment-free period of several days should precede any repeated use. Permanent use of decongestant rhinological agents may attenuate their effect. The abuse of local rhinological agents may cause mucosal atrophy and reactive hyperaemia with rhinitis medicamentosa. Longer use of oxymetazoline may cause damage to the mucosal epithelium with inhibition of ciliary activity. This may possibly result in irreversible damage to the mucosa with rhinitis sicca. Long term use and overdosage must be avoided, especially in children. Medical supervision is indicated in patients with chronic rhinitis. Dosage higher than recommended may only be used under supervision.
NASAL
Medical Information
**Indications** Acute cold, paranasal sinusitis, syringitis, otitis media.
**Contraindications** Rhinitis sicca, hypersensitivity to the active ingredient or to any of the excipients, infants and small children below 1 year of age. In the following cases this drug may only be used after carefully weighing the risk-to-benefit ratio: - Patients treated with monamine oxidase inhibitors (MAO-inhibitors) and other drugs potentially increasing blood pressure - Increased intraocular pressure, especially narrow-angle glaucoma - Severe cardiovascular diseases (e.g. coronary heart disease, hypertension) - Phaeochromocytoma - Metabolic disorders (e.g. hyperthyroidism, diabetes mellitus, porphyria). - Hyperplasia of the prostate Because of the benzalkonium chloride which is contained as preservative, Iliadin 0.025% Decongestant Nasal Drops must not be used in known hypersensitivity to this substance.
R01AA05
oxymetazoline
Manufacturer Information
PROCTER & GAMBLE (SINGAPORE) PTE LTD
Delpharm Bladel B.V.
SOFARIMEX - INDUSTRIA QUIMICA E FARMACEUTICA, S.A.
Active Ingredients
Documents
Patient Information Leaflets
07g. Iliadin 0.025% soln PIL Proposed Clean.pdf
Approved: May 4, 2020